Search
Documentation Center

Analysis of Prescription Drug Utilization with Beta Regression Models
Recurso electrónico / Electronic resource
MARC record
Tag12Value
LDR  00000cab a2200000 4500
001  MAP20220017589
003  MAP
005  20220613141619.0
008  220613e20220613esp|||p |0|||b|spa d
040  ‎$a‎MAP‎$b‎spa‎$d‎MAP
084  ‎$a‎6
1001 ‎$0‎MAPA20140000234‎$a‎Gan, Guojun ‌
24510‎$a‎Analysis of Prescription Drug Utilization with Beta Regression Models‎$c‎Guojun Gan, Emiliano A. Valdez
520  ‎$a‎The health care sector in the United States is complex and is also a large sector that generates about 20% of the country's gross domestic product. Health care analytics has been used by researchers and practitioners to better understand the industry. In this article, we examine and demonstrate the use of Beta regression models to study the utilization of brand name drugs in the United States to understand the variability of brand name drug utilization across different areas. The models are fitted to public datasets obtained from the Medicare & Medicaid Services and the Internal Revenue Service. Integrated nested Laplace approximation (INLA) is used to perform the inference. The numerical results show that Beta regression models can fit the brand name drug claim rates well and including spatial dependence improves the performance of the Beta regression models. Such models can be used to reflect the effect of prescription drug utilization when updating an insured's health risk in a risk scoring model.
650 4‎$0‎MAPA20080540821‎$a‎Drogas ‌
650 4‎$0‎MAPA20080563288‎$a‎Medicamentos ‌
650 4‎$0‎MAPA20080606633‎$a‎Industria farmacéutica ‌
651 1‎$0‎MAPA20080638337‎$a‎Estados Unidos ‌
7001 ‎$0‎MAPA20080648428‎$a‎Valdez, Emiliano A. ‌
7730 ‎$w‎MAP20077000239‎$g‎13/06/2022 Tomo 26 Número 2 - 2022 , p. 205-226‎$x‎1092-0277‎$t‎North American actuarial journal‎$d‎Schaumburg : Society of Actuaries, 1997-